Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
rozanolixizumab
- Development stage
- Approved
- Lead developer
- UCB
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Subcutaneous
01
Overview
Rozanolixizumab is a humanized monoclonal antibody that targets the neonatal Fc receptor (FcRn). It is used for the treatment of generalized myasthenia gravis (gMG) in adults who are positive for anti-acetylcholine receptor (AChR) or anti-muscle-specific tyrosine kinase (MuSK) antibodies. By binding to FcRn, rozanolixizumab blocks the recycling and rescue of immunoglobulin G (IgG), leading to a reduction in circulating pathogenic IgG autoantibodies. This mechanism helps decrease immune-mediated damage at neuromuscular junctions, improving muscle function in patients with gMG. Rozanolixizumab was developed by UCB and is marketed under the brand name Rystiggo[1][2][3][5][6][8].
- Brand names
- Rystiggo
- Other names
- rozanolixizumab-noli
02
Targets
FCGRT (Neonatal crystallizable fragment receptor)
Beyond the preview
Go deeper on rozanolixizumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on rozanolixizumab.